Mirum Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) on June 6, 2022, covering events occurring on June 2, 2022. The filing details the appointment of a new director and the results of the Company's 2022 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate governance and shareholder voting outcomes rather than financial performance.
Material Changes and Corporate Actions
- Board Appointment: On June 2, 2022, the Board appointed Saira Ramasastry as a Class II director, effective immediately. She will serve on the Audit Committee, succeeding Niall O'Donnell, Ph.D.
- Director Compensation: Ms. Ramasastry received a stock option to purchase 34,000 shares (vesting in three equal annual installments), an annual cash retainer of $40,000, and an additional $10,000 for Audit Committee service. Future annual option grants of 17,000 shares are eligible starting in 2023.
- Annual Meeting Results: The meeting was held on June 2, 2022, with 31,815,969 shares outstanding as of the April 8, 2022 record date.
Voting Outcomes
| Proposal | Outcome | Key Vote Counts |
|---|---|---|
| Proposal 1: Election of Directors (Class III: Laura Brege, Michael Grey, Christopher Peetz) |
Approved | Laura Brege: 17,902,179 For / 5,742,160 Withheld Michael Grey: 18,080,299 For / 5,564,040 Withheld Christopher Peetz: 19,163,580 For / 4,480,759 Withheld |
| Proposal 2: Ratification of Auditor (Ernst & Young LLP) |
Approved | 25,925,952 For / 5,169 Against / 17,948 Abstentions |
Outlook, Risks, and Contingencies
The filing does not contain management commentary on future outlook, specific risks, or contingencies beyond the standard disclosure that there were no related person transactions or undisclosed arrangements regarding the new director's appointment.
Key Facts for Investor Verification
- Verify the vesting schedule and exercise price of the 34,000 stock options granted to Saira Ramasastry.
- Confirm the total number of shares outstanding and the impact of the new director's option grant on potential dilution.
- Review the full text of the press release (Exhibit 99.1) for additional context on the new director's qualifications.
- Note that the filing does not include updated financial statements; refer to the most recent 10-Q or 10-K for financial health.